BR112015005997A8 - Composto - Google Patents

Composto

Info

Publication number
BR112015005997A8
BR112015005997A8 BR112015005997A BR112015005997A BR112015005997A8 BR 112015005997 A8 BR112015005997 A8 BR 112015005997A8 BR 112015005997 A BR112015005997 A BR 112015005997A BR 112015005997 A BR112015005997 A BR 112015005997A BR 112015005997 A8 BR112015005997 A8 BR 112015005997A8
Authority
BR
Brazil
Prior art keywords
hiv
aids
oxo
methyl
treatment
Prior art date
Application number
BR112015005997A
Other languages
English (en)
Other versions
BR112015005997A2 (pt
Inventor
K Maguire Courtney
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112015005997A2 publication Critical patent/BR112015005997A2/pt
Publication of BR112015005997A8 publication Critical patent/BR112015005997A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO. O retrovírus chamado de vírus da imunodeficiência humana (HIV), particularmente as cepas conhecidas como HIV de tipo-1 (HIV-1) e HIV de tipo-2 (HIV-2), tem estado etiologicamente ligado à doença imunossupressiva conhecida como síndrome da imunodeficiência adquirida (AIDS). Os indivíduos soropositivos para HIV são inicialmente assintomáticos, mas de modo típico desenvolvem complexo relacionado com AIDS (ARC) seguido pela AIDS. Os indivíduos afetados apresentam imunossupressão severa que os torna elevadamente suscetíveis às infecções debilitadoras e finalmente às infecções oportunísticas fatais. A invenção refere-se a uma nova forma cristalina do inibidor de RT (transcriptase reversa), a saber, 3-cloro-5-({1-[(4-metil-5-oxo-4,5-di-hidro-1H-1,2,4-triazol-3-il)metil]-2-oxo-4-(trifluorometil)-1,2-di-hidropiridin-3-il}oxi)benzonitrila, que é usada no tratamento de infecção causada por HIV e no tratamento de AIDS.
BR112015005997A 2012-09-26 2013-09-20 Composto BR112015005997A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Publications (2)

Publication Number Publication Date
BR112015005997A2 BR112015005997A2 (pt) 2017-07-04
BR112015005997A8 true BR112015005997A8 (pt) 2023-04-11

Family

ID=50388877

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005997A BR112015005997A8 (pt) 2012-09-26 2013-09-20 Composto

Country Status (9)

Country Link
US (1) US9150539B2 (pt)
EP (1) EP2900240B1 (pt)
JP (2) JP6387349B2 (pt)
CN (2) CN104684557A (pt)
BR (1) BR112015005997A8 (pt)
CA (1) CA2882947A1 (pt)
ES (1) ES2773105T3 (pt)
MX (1) MX362517B (pt)
WO (1) WO2014052171A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3617193B1 (en) 2013-12-04 2024-03-27 Merck Sharp & Dohme LLC Process for making reverse transcriptase inhibitors
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309700B2 (en) 2004-04-02 2007-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one
MX2007000788A (es) * 2004-07-27 2007-03-23 Hoffmann La Roche Compuestos de benciltriazolona como inhibidores no nucleosidos de transcriptasa inversa.
CA2687770C (en) * 2007-05-30 2016-03-08 F. Hoffmann-La Roche Ag Process for preparing triazolones
RU2010125220A (ru) * 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
US20130040914A1 (en) 2010-04-08 2013-02-14 Samson M. Jolly Prodrugs of an hiv reverse transcriptase inhibitor

Also Published As

Publication number Publication date
BR112015005997A2 (pt) 2017-07-04
JP2018024683A (ja) 2018-02-15
ES2773105T3 (es) 2020-07-09
EP2900240A4 (en) 2016-07-13
MX362517B (es) 2019-01-21
MX2015003767A (es) 2015-07-14
CN104684557A (zh) 2015-06-03
EP2900240A1 (en) 2015-08-05
JP2015531372A (ja) 2015-11-02
EP2900240B1 (en) 2020-01-08
WO2014052171A1 (en) 2014-04-03
JP6387349B2 (ja) 2018-09-05
US20150232447A1 (en) 2015-08-20
CA2882947A1 (en) 2014-04-03
CN109384765A (zh) 2019-02-26
US9150539B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CU24340B1 (es) Derivados de acetamidas fluoradas para el tratamiento del vih
MX2007006561A (es) Uso de acido(s) graso s) omega-3 para el tratamiento de la hipercolesterolemia causada por el tratamiento antirretroviral de los pacientes infectados con vih.
UY37592A (es) Compuestos inhibidores del vih
CL2015000880A1 (es) Compuestos heterociclicos derivados de 4-pirimidinona, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; uso en la profilaxis o el tratamiento de infeccion por vih o para la profilaxis, tratamiento o retraso de la aparicion del sida en un sujeto.
BR112022001520A2 (pt) Complexo de peptídeos bicíclicos em heterotandem
CL2008000862A1 (es) Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1.
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
EA201790306A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CL2015001538A1 (es) Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
RU2017128643A (ru) Новое производное хинолина для применения в лечении и профилактике вирусных инфекций
WO2012051492A3 (en) Compounds and methods for inhibiting hiv latency
BR112015005997A8 (pt) Composto
CL2009000636A1 (es) Compuestos derivados de 1-(1h-pirazol-3-il)-imidazolidin-4-ona sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de enfermedades retrovirales, tal como infeccion por vih.
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
PE20130529A1 (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
JP2013508349A5 (pt)
BR112015012843B8 (pt) Método para sintetizar o composto
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
BR112022023897A2 (pt) Um composto de azelastina para uso como substância antiviral, uso de um composto de azelastina como desinfetante
BR112021017158A2 (pt) Composto e composição farmacêutica compreendendo o mesmo
BR112013028698A8 (pt) Compostos para uso no tratamento de infecções retrovirais em felinos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)